Again, like every other company they've got a couple of weeks to list the trial AFTER firstpatient injected.

Again, they take their time/work to make everything in the BLA exactly like FDA liked in order to avoid a CRL/decline of application.

Since leronlimab is safe and highly effacious, only manufacturing could be an issue, but AGC is a decent company and they took their time.

So, once BLA is submitted, 5% chance it gets rejected IMO.